|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Carrasco-Garcia E, Auzmendi-Iriarte J and
Matheu A: Integrin α7: A novel promising target in glioblastoma
stem cells. Stem Cell Investig. 5(2)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ming XY, Fu L, Zhang LY, Qin YR, Cao TT,
Chan KW, Ma S, Xie D and Guan XY: Integrin α7 is a functional
cancer stem cell surface marker in oesophageal squamous cell
carcinoma. Nat Commun. 7(13568)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hsu YL, Hung JY, Liang YY, Lin YS, Tsai
MJ, Chou SH, Lu CY and Kuo PL: S100P interacts with integrin α7 and
increases cancer cell migration and invasion in lung cancer.
Oncotarget. 6:29585–29598. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tan LZ, Song Y, Nelson J, Yu YP and Luo
JH: Integrin α7 binds tissue inhibitor of metalloproteinase 3 to
suppress growth of prostate cancer cells. Am J Pathol. 183:831–840.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nunes AM, Barraza-Flores P, Smith CR and
Burkin DJ: Integrin α7: A major driver and therapeutic target for
glioblastoma malignancy. Stem Cell Investig. 4(97)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Burkin DJ and Fontelonga TM: Mesothelioma
cells breaking bad: Loss of integrin α7 promotes cell motility and
poor clinical outcomes in patients. J Pathol. 237:282–284.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Haas TL, Sciuto MR, Brunetto L, Valvo C,
Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A,
et al: Integrin α7 Is a Functional Marker and Potential Therapeutic
Target in Glioblastoma. Cell Stem Cell. 21:35–50.e9.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhu ZH, Yu YP, Zheng ZL, Song Y, Xiang GS,
Nelson J, Michalopoulos G and Luo JH: Integrin alpha 7 interacts
with high temperature requirement A2 (HtrA2) to induce prostate
cancer cell death. Am J Pathol. 177:1176–1186. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bai X, Gao C, Zhang L and Yang S: Integrin
α7 high expression correlates with deteriorative tumor features and
worse overall survival, and its knockdown inhibits cell
proliferation and invasion but increases apoptosis in breast
cancer. J Clin Lab Anal. 33(e22979)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Su Y, Guan XQ, Liu FQ and Wang YL: The
effects of MIBG on the invasive properties of HepG2 hepatocellular
carcinoma cells. Int J Mol Med. 34:842–848. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao
UN, Nelson J, Michalopoulos GK and Luo JH: Analysis of integrin
alpha7 mutations in prostate cancer, liver cancer, glioblastoma
multiforme, and leiomyosarcoma. J Natl Cancer Inst. 99:868–880.
2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gyuris J, Golemis E, Chertkov H and Brent
R: Cdi1, a human G1 and S phase protein phosphatase that associates
with Cdk2. Cell. 75:791–803. 1993.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hannon GJ, Casso D and Beach D: KAP: A
dual specificity phosphatase that interacts with cyclin-dependent
kinases. Proc Natl Acad Sci USA. 91:1731–1735. 1994.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kawashima T, Hirose K, Satoh T, Kaneko A,
Ikeda Y, Kaziro Y, Nosaka T and Kitamura T: MgcRacGAP is involved
in the control of growth and differentiation of hematopoietic
cells. Blood. 96:2116–2124. 2000.PubMed/NCBI
|
|
20
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y,
Lu L and Liu Z: Dopamine-induced SULT1A3/4 promotes EMT and cancer
stemness in hepatocellular carcinoma. Tumour Biol.
39(1010428317719272)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Santamaria PG, Moreno-Bueno G, Portillo F
and Cano A: EMT: Present and future in clinical oncology. Mol
Oncol. 11:718–738. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nistico P: Bissell MJandRadisky DC:
Epithelial-mesenchymal transition: general principles and
pathological relevance with special emphasis on the role of matrix
metalloproteinases. Cold Spring Harb Perspect Biol.
4(a011908)2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gaianigo N: Melisi D and Carbone C: EMT
and Treatment Resistance in Pancreatic Cancer. Cancers (Basel).
9(122)2017.PubMed/NCBI View Article : Google Scholar
|
